Linked Life Data

17721388

Source:http://linkedlifedata.com/resource/pubmed/id/17721388

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2007-8-27
pubmed:abstractText
This retrospective review evaluates the response to caspofungin when given to children with febrile neutropenia and describes adverse effects attributable to caspofungin, including risk of hepatotoxicity during concomitant therapy with cyclosporine. Sixty-seven courses of caspofungin administered to 56 patients (1-17 years) were surveyed; 53 (79%) courses resulted in an overall favorable response. Ten children (15% of courses) experienced an adverse drug-related event that was probably or possibly attributable to caspofungin. Rash and hypokalemia were the most commonly identified adverse effects. One of 19 children receiving caspofungin and cyclosporine concurrently developed hepatotoxicity possibly related to caspofungin.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0891-3668
pubmed:author
pubmed:issnType
Print
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
854-6
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children.
pubmed:affiliation
Department of Pharmacy, The Hospital for Sick Children, Toronto, ONT, Canada. alicia.koo@sickkids.ca
pubmed:publicationType
Journal Article